Its efficacy in lowering blood sugar levels and contributing to weight loss has been widely acknowledged
The challenge is to get these results into clinical practice, to get the drug used by the people who will benefit from it, who will live longer without dialysis, without heart attacks, without strokes, if they take this drug. Novo Nordisk will need to seek regulatory approval for semaglutide to be used to treat those with chronic kidney disease
Clinically, in patients with renal failure, acute kidney injury, dialysis and other pathological states of renal function deterioration, renal reabsorption function is impaired, resulting in a significantly lower serum free carnitine concentration than that in healthy people [255], and the metabolic profile of acylcarnitine also changes significantly [256]
Whether its medically supervised, self-managed, or completely unrelated to GLP-1s, we meet you where youre at
They can help determine if tirzepatide may be a better fit
The cost of GLP-1 pills may also increase their accessibility Cost-wise, it looks like peptide pills and drops (once FDA-approved), will be the most affordable option